Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Bicalutamide + Raloxifene |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bicalutamide | Casodex | Hormone - Anti-androgens 54 | Casodex (bicalutamide) is an androgen-receptor antagonist that binds androgen receptors and inhibits androgen binding, therefore inhibits AR-dependent growth of tumor cells (PMID: 9428389). Casodex (bicalutamide) is approved, in combination with a luteinizing hormone-releasing hormone (LHRH) analog, for metastatic carcinoma of the prostate (FDA.gov). | |
Raloxifene | Evista | LY-139481 | Hormone - Anti-estrogens 29 | Evista (raloxifene) is a selective estrogen receptor modulator (SERM), which can act as an estrogen antagonist and is FDA approved for breast cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03147196 | Phase II | Bicalutamide + Raloxifene Raloxifene Bicalutamide | Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | Withdrawn | 0 |